Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2012

Filed with the SEC on Nov 7, 2012 and accepted by EDGAR at Nov 7, 2012, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2012-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2012-07-01 to 2012-09-30$3.7mus-gaap:Revenues
Revenue9 months2012-01-01 to 2012-09-30$33.7mus-gaap:Revenues
Cost of revenue3 months2012-07-01 to 2012-09-30$2.4mus-gaap:CostOfRevenue
Cost of revenue9 months2012-01-01 to 2012-09-30$7.0mus-gaap:CostOfRevenue
Gross profit3 months2012-07-01 to 2012-09-30$3.0mus-gaap:GrossProfit
Gross profit9 months2012-01-01 to 2012-09-30$27.4mus-gaap:GrossProfit
Research and development3 months2012-07-01 to 2012-09-30$8.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2012-01-01 to 2012-09-30$27.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2012-07-01 to 2012-09-30−$5.6mus-gaap:OperatingIncomeLoss
Operating income9 months2012-01-01 to 2012-09-30−$2.0mus-gaap:OperatingIncomeLoss
Net income3 months2012-07-01 to 2012-09-30−$5.5mus-gaap:NetIncomeLoss
Net income9 months2012-01-01 to 2012-09-30−$1.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2012-07-01 to 2012-09-30−$0.06us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2012-01-01 to 2012-09-30−$0.02us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2012-01-01 to 2012-09-30−$1.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2012-01-01 to 2012-09-30$1.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2012-09-30$50.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2012-09-30$59.6mus-gaap:AssetsCurrent
Total assetsAt period end2012-09-30$77.4mus-gaap:Assets
Current liabilitiesAt period end2012-09-30$20.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2012-09-30$72.6mus-gaap:Liabilities
Long-term debtAt period end2012-09-30$2.8mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2012-09-30$4.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-12-060041. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.